CO2022008835A2 - Agonistas del tlr7 - Google Patents

Agonistas del tlr7

Info

Publication number
CO2022008835A2
CO2022008835A2 CONC2022/0008835A CO2022008835A CO2022008835A2 CO 2022008835 A2 CO2022008835 A2 CO 2022008835A2 CO 2022008835 A CO2022008835 A CO 2022008835A CO 2022008835 A2 CO2022008835 A2 CO 2022008835A2
Authority
CO
Colombia
Prior art keywords
tlr7 agonists
diseases
tlr7
agonists
cancer
Prior art date
Application number
CONC2022/0008835A
Other languages
English (en)
Inventor
Stephen E Webber
James Richard Appleman
Original Assignee
Primmune Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Primmune Therapeutics Inc filed Critical Primmune Therapeutics Inc
Publication of CO2022008835A2 publication Critical patent/CO2022008835A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)

Abstract

La presente invención se refiere a agonistas de TLR7 según la fórmula I y su uso en el tratamiento de enfermedades como el cáncer y las enfermedades infecciosas. (I)
CONC2022/0008835A 2019-11-26 2022-06-24 Agonistas del tlr7 CO2022008835A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962940622P 2019-11-26 2019-11-26
PCT/US2020/062344 WO2021108649A1 (en) 2019-11-26 2020-11-25 Tlr7 agonists

Publications (1)

Publication Number Publication Date
CO2022008835A2 true CO2022008835A2 (es) 2022-07-19

Family

ID=75974715

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0008835A CO2022008835A2 (es) 2019-11-26 2022-06-24 Agonistas del tlr7

Country Status (17)

Country Link
US (2) US11692005B2 (es)
EP (1) EP4065155A4 (es)
JP (1) JP2023503996A (es)
KR (1) KR20220150879A (es)
CN (1) CN115427063A (es)
AU (1) AU2020391487A1 (es)
BR (1) BR112022010165A2 (es)
CA (1) CA3163093A1 (es)
CL (1) CL2022001377A1 (es)
CO (1) CO2022008835A2 (es)
CR (1) CR20220282A (es)
EC (1) ECSP22049906A (es)
IL (1) IL293293A (es)
MX (1) MX2022006307A (es)
PE (1) PE20221324A1 (es)
TW (1) TW202134240A (es)
WO (1) WO2021108649A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114917228B (zh) * 2022-06-07 2023-09-26 广西中医药大学 一种用于预防性治疗狂犬病的药方及其制备方法与应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5476659A (en) 1982-11-09 1995-12-19 The Scripps Research Institute Cancerous B cell treatment using substituted nucleoside derivatives
US5011828A (en) 1985-11-15 1991-04-30 Michael Goodman Immunostimulating guanine derivatives, compositions and methods
US5136030A (en) 1988-05-05 1992-08-04 Scripps Clinic And Research Foundation Immunostimulating guanine derivatives, compositions and methods
US5093319A (en) 1989-10-31 1992-03-03 Pfizer Hospital Products Group, Inc. Use of derivatives of chitin soluble in aqueous solutions for preventing adhesions
AU5845594A (en) 1992-11-13 1994-06-08 Scripps Research Institute, The Cancerous b cell treatment using substituted nucleoside derivatives
ATE271063T1 (de) 1996-10-16 2004-07-15 Icn Pharmaceuticals Purin-l-nukleoside, deren analoga und verwendungen
TR200601784T2 (tr) 1999-11-12 2007-01-22 Pharmasset Ltd. 2'-deoksi-L-nükleositlerin sentezi
NZ521210A (en) 2000-02-18 2004-11-26 Shire Biochem Inc Method for the treatment or prevention of flavivirus infections using nucleoside analogues
PT1411954E (pt) 2000-10-18 2011-03-16 Pharmasset Inc Nucleosídeos modificados para o tratamento de infecções virais e proliferação celular anormal
CA2537450C (en) 2003-09-05 2012-04-17 Anadys Pharmaceuticals, Inc. Administration of tlr7 ligands and prodrugs thereof for treatment of infection by hepatitis c virus
TWI407956B (zh) 2004-12-17 2013-09-11 Anadys Pharmaceuticals Inc ３，５-二取代和３，５，７-三取代-３Ｈ-唑并及３Ｈ-噻唑并〔４，５-ｄ〕嘧啶-２-酮化合物及其前藥
AU2008286735A1 (en) 2007-08-15 2009-02-19 Idera Pharmaceuticals, Inc. Toll like receptor modulators
CA2732437C (en) 2008-08-01 2017-11-21 Ventirx Pharmaceuticals, Inc. Toll-like receptor agonist formulations and their use
WO2010111290A1 (en) 2009-03-23 2010-09-30 University Of Utah Research Foundation Methods and compositions related to modified guanine bases for controlling off-target effects in rna interference
CN104661683A (zh) 2011-11-09 2015-05-27 埃森德生物制药有限公司 免疫调节缀合物
KR102462743B1 (ko) 2014-07-09 2022-11-02 버디 바이오파마슈티칼즈, 인크. 종양 치료용 항-pd-l1 조합
PL3230298T3 (pl) 2014-12-08 2021-06-14 F.Hoffmann-La Roche Ag 3-podstawione związki 5-amino-6h-tiazolo[4,5-d]pirymidyno-2,7-dionowe do leczenia i profilaktyki zakażenia wirusowego
SG10201912847QA (en) 2015-03-16 2020-02-27 Hoffmann La Roche Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor
CN115554406A (zh) 2016-01-07 2023-01-03 博笛生物科技有限公司 用于治疗肿瘤的抗-cd20组合
NZ755222A (en) 2016-12-20 2022-07-01 Astrazeneca Ab Amino-triazolopyridine compounds and their use in treating cancer
KR20210035095A (ko) 2018-05-25 2021-03-31 프리뮨 테라퓨틱스, 인크. Tlr7 효능제

Also Published As

Publication number Publication date
MX2022006307A (es) 2022-08-22
IL293293A (en) 2022-07-01
ECSP22049906A (es) 2022-07-29
BR112022010165A2 (pt) 2022-08-09
US20210155652A1 (en) 2021-05-27
JP2023503996A (ja) 2023-02-01
KR20220150879A (ko) 2022-11-11
TW202134240A (zh) 2021-09-16
US11692005B2 (en) 2023-07-04
EP4065155A4 (en) 2023-11-29
CN115427063A (zh) 2022-12-02
CA3163093A1 (en) 2021-06-03
CR20220282A (es) 2022-11-28
EP4065155A1 (en) 2022-10-05
PE20221324A1 (es) 2022-09-09
WO2021108649A1 (en) 2021-06-03
CL2022001377A1 (es) 2023-04-10
US20240116974A1 (en) 2024-04-11
AU2020391487A1 (en) 2022-07-07

Similar Documents

Publication Publication Date Title
ECSP20020410A (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
CO2020016131A2 (es) Agonistas de tlr7
CO2020010956A2 (es) Composiciones y métodos para el tratamiento del cáncer y de trastornos inmunitarios usando bacterias de veillonella
ECSP19057713A (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas para el tratamiento del cáncer
ECSP12011830A (es) Nuevos compuestos.
ECSP20084434A (es) Tiofenocarboxamidas sustituidas y análogos como agentes antibacterianos
MX2020003495A (es) Derivados de acido boronico y sintesis de los mismos.
DOP2016000170A (es) Compuestos derivados de hidroxiformamida y usos del mismo
CO2020003475A2 (es) Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos
CO2022008835A2 (es) Agonistas del tlr7
CO2018008157A2 (es) Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
DOP2019000221A (es) Derivados de pirazol como inhibidores de bromodominio
CL2018002368A1 (es) Formulaciones de oritavancina
CR20170157A (es) Derivados de nucleósidos sustituidos con 4´-vinilo como inhibidores de la replicación del arn del virus respiratorio sincitial
BR112022004777A2 (pt) Composição de micela de estimulação imunológica
UY35610A (es) Derivados de prodroga de triazolpiridinas sustituidas
CL2020000127A1 (es) Moduladores terapéuticos del modo inverso de la atp sintasa.
CO2018007756A2 (es) Nuevos derivados pirrolidina
CR20150641U (es) Composiciones farmacéuticas
AR111715A1 (es) ANTICUERPOS ANTI-SIRPa
MX2020004871A (es) Derivados de acido cafeico y sus usos.
AR123554A1 (es) Composiciones y métodos para el tratamiento de la inflamación usando prevotella histicola
AR099340A1 (es) Conjugados del factor de coagulación ix
CO2019006311A2 (es) N-acetilcisteína para su uso como agente antibacteriano